Implementation of patient education at first and second dispensing of statins in Dutch community pharmacies: the sequel of a cluster randomized trial

Caroline H P A Van de Steeg-van Gompel, Michel Wensing, Peter A G M De Smet, Caroline H P A Van de Steeg-van Gompel, Michel Wensing, Peter A G M De Smet

Abstract

Background: As a result of the previous part of this trial, many patients with cardiovascular disease were expected to receive a statin for the first time. In order to provide these patients with comprehensive information on statins, as recommended by professional guidance, education at first and second dispensing of statins had to be implemented. This study was designed to assess the effectiveness of an intensive implementation program targeted at pharmacy project assistants on the frequency of providing education at first dispensing (EAFD) and education at second dispensing (EASD) of statins in community pharmacies.

Methods: The participating community pharmacies were clustered on the basis of local collaboration, were numbered by a research assistant and subsequently an independent statistician performed a block randomization, in which the cluster size (number of pharmacies in each cluster) was balanced. The pharmacies in the control group received a written manual on the implementation of EAFD and EASD; the pharmacies in the intervention group received intensive support for the implementation. The impact of the intensive implementation program on the implementation process and on the primary outcomes was examined in a random coefficient logistic regression model, which took into account that patients were grouped within pharmacy clusters.

Results: Of the 37 pharmacies in the intervention group, 17 pharmacies (50%) provided EAFD and 12 pharmacies (35.3%) provided EASD compared to 14 pharmacies (45.2%, P = 0.715) and 12 pharmacies (38.7%, P = 0.899), respectively, of the 34 pharmacies in the control group. In the intervention group a total of 72 of 469 new statin users (15.4%) received education and 49 of 393 patients with a second statin prescription (12.5%) compared to 78 of 402 new users (19.4%, P = 0.944) and 35 of 342 patients with a second prescription (10.2%, P = 0.579) in the control group.

Conclusion: The intensive implementation program did not increase the frequency of providing EAFD and EASD of statins in community pharmacies.

Trial registration: clinicaltrials.gov NCT00509717.

Figures

Figure 1
Figure 1
Participant flow.

References

    1. van de Steeg-van Gompel CH, Wensing M, De Smet PA. Implementation of a pharmacist-led intervention to enhance statin prescribing for secondary prevention in primary care: a cluster randomized trial. Eur J Cardiovasc Prev Rehabil. 2011. in press .
    1. KNMP. Nederlandse Apotheek Norm (NAN) 2006. Richtlijn 2: Farmaceutische zorg- en dienstverlening. Last accessed: June 28 2011.
    1. Puspitasari HP, Aslani P, Krass I. A review of counseling practices on prescription medicines in community pharmacies. Res Social Adm Pharm. 2009;5:197–210. doi: 10.1016/j.sapharm.2008.08.006.
    1. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf. 2008;7:717–725. doi: 10.1517/14740330802396984.
    1. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10:2973–2985. doi: 10.1517/14656560903376186.
    1. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59:564–573. doi: 10.1111/j.1365-2125.2005.02355.x.
    1. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005;21:485–488.
    1. Amar J, Ferrières J, Cambou JP, Amelineau E, Danchin N. Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes. Arch Cardiovasc Dis. 2008;101:301–306. doi: 10.1016/j.acvd.2008.04.005.
    1. Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke. Stroke. 2010;41:397–401. doi: 10.1161/STROKEAHA.109.566950.
    1. Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL. Long-term Medication Adherence after Myocardial Infarction: Experience of a Community. Am J Med. 2009;122:961.
    1. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: A retrospective analysis. Clin Ther. 2005;27:1806–1814. doi: 10.1016/j.clinthera.2005.11.003.
    1. van de Steeg-van Gompel C, Wensing M, De Smet PAGM. Implementation of a discontinuation letter to reduce long-term benzodiazepine use--A cluster randomized trial. Drug Alcohol Depend. 2009;99:105–114. doi: 10.1016/j.drugalcdep.2008.07.009.
    1. Pronk M, Blom L, Jonkers R, Bakker A. Community pharmacy and patient-oriented activities: the Dutch case. Patient Educ Couns. 2002;46:39–45. doi: 10.1016/S0738-3991(01)00148-3.
    1. Pronk MC, Blom AT, Jonkers R, Van BA. The diffusion process of patient education in Dutch community pharmacy: an exploration. Patient Educ Couns. 2001;42:115–121. doi: 10.1016/S0738-3991(00)00091-4.
    1. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003;362:1225–1230. doi: 10.1016/S0140-6736(03)14546-1.
    1. Bosch M, van der WT, Wensing M, Grol R. Tailoring quality improvement interventions to identified barriers: a multiple case analysis. J Eval Clin Pract. 2007;13:161–168. doi: 10.1111/j.1365-2753.2006.00660.x.
    1. Grol R, Wensing M. In: Improving Patient Care. The Implementation of Change in Clinical Practice. Grol R, Wensing M, Eccles M, editor. London, Elsevier Butterworth Heinemann; 2005. Effective implementation: a model; pp. 41–57.
    1. Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust. 2003;179:438–440.
    1. Muijrers PE, Knottnerus JA, Sijbrandij J, Janknegt R, Grol RP. Pharmacists in primary care. Determinants of the care-providing function of Dutch community pharmacists in primary care. Pharm World Sci. 2004;26:256–262.
    1. Ten Wolde G, Dijkstra A, Van Empelen P, Knuistingh Neven A, Zitman F. Psychological determinants of the intention to educate patients about benzodiazepines. Pharm World Sci. 2008;30:336–342. doi: 10.1007/s11096-007-9183-2.
    1. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008. p. CD000011.
    1. Mann DM, Ponieman D, Montori VM, Arciniega J, McGinn T. The Statin Choice decision aid in primary care: A randomized trial. Patient Educ Couns. 2010;80:138–140. doi: 10.1016/j.pec.2009.10.008.
    1. Geurts MME, Pot JLW, Schepers EH, Tromp C, Colijn CG, Dijkstra A, de Gier JJ. The evaluation of an intervention based on the application of patient self-completion concordance forms in Dutch community pharmacies and the effect on adherence to chronic medication. Patient Educ Couns. 2010;78:85–90. doi: 10.1016/j.pec.2009.04.005.
    1. Casebeer L, Huber C, Bennett N, Shillman R, Abdolrasulnia M, Salinas G, Zhang S. Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract. 2009;10:48. doi: 10.1186/1471-2296-10-48.
    1. Jelinek M, Vale MJ, Liew D, Grigg L, Dart A, Hare DL, Best JD. The COACH Program Produces Sustained Improvements in Cardiovascular Risk Factors and Adherence to Recommended Medications--Two Years Follow-up. Heart Lung Circ. 2009;18:388–392. doi: 10.1016/j.hlc.2009.06.001.
    1. Willich SN, Englert H, Sonntag F, Voller H, Meyer-Sabellek W, Wegscheider K, Windler E, Katus H, Muller-Nordhorn J. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. Eur J Cardiovasc Prev Rehabil. 2009;16:180–187. doi: 10.1097/HJR.0b013e3283262ac3.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe